Schwendenman Andrew
Known title: Chief Accounting OfficerCIK: 0001977879
Associated companies
Transaction History
| REPL | ▼ Sell | Open Market | 7,632 | $99K | 8/10/2026 | View on chart |
| REPL | ▼ Sell | Open Market | 7,894 | $40K | 5/18/2026 | View on chart |
| REPL | ▲ Buy | Grant | 36,667 | $0 | 4/1/2026 | View on chart |
| REPL | ▲ Buy | Grant | 10,000 | $0 | 12/19/2025 | View on chart |
| REPL | ▼ Sell | Open Market | 3,287 | $26K | 5/20/2025 | View on chart |
| REPL | ▲ Buy | Grant | 33,333 | $0 | 4/1/2025 | View on chart |
| REPL | ▼ Sell | Open Market | 2,298 | $15K | 5/16/2024 | View on chart |
| REPL | ▲ Buy | Grant | 17,775 | $0 | 4/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Replimune Launches TUDRIQEV Amidst Mixed Analyst Views
Replimune Group has launched TUDRIQEV, marking a key step in its commercial strategy. Analysts are currently assessing the product's potential, with some suggesting a wait-and-see approach until market performance becomes clearer. The stock is trading near significant support levels, reflecting cautious sentiment as investors evaluate the new launch.
Replimune Launches TUDRIQEV Amidst Mixed Analyst Views. Replimune Group has launched TUDRIQEV, marking a key step in its commercial strategy. Analysts are currently assessing the product's potential, with some suggesting a wait-and-see approach until market performance becomes clearer. The stock is trading near significant support levels, reflecting cautious sentiment as investors evaluate the new launch.